Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis

Figure 2

Frequencies of CD4⁺T cell subset in RA patients before and after therapy. The proportion of IFN-γ⁺Th1, IL-17⁺Th17, circulating CD4⁺CCRPD-Tfh, and CD4⁺CD25⁺Foxp3⁺Treg in CD4⁺T cells was analyzed by flow cytometry on 0 w, 24 w, and 52 w. (a) Representative staining data showing the proportion of Th1. (b) Representative staining data showing the proportion of Th17. (c) Representative staining data showing the proportion of Tfh. (d) Representative staining data showing the proportion of Treg. (e) Collated data showing the proportion of Th1. (f) Collated data showing the proportion of Th17. (g) Collated data showing the proportion of Tfh. (h) Collated data showing the proportion of Treg. , , and are statistically significant compared to 24 w. , , and are statistically significant compared to 0 w. Group A: iguratimod was administered to patients for 52 weeks. Group B: placebo was administered to patients for the first 24 weeks and iguratimod was administered to patients for the subsequent 28 weeks.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)